MALVERN, PA - (HSMN NewsFeed) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL ), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee confirmed it will review XIAFLEX(TM) durin…
Biopharmaceuticals, FDA
Auxilium Pharmaceuticals, XIAFLEX, collagenase, Dupuytren’s

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “U.S. Food and Drug Administration’s Arthritis Advisory Committee Confirms Date to Review XIAFLEX(TM) for the Treatment of Dupuytren’s Contracture”
Leave a Comment